Tumor angiogenesis and endothelial cell modulatory factors

Journal of Immunotherapy

Volumn 22, Issue 3, 1999, Pages 186-211

  Desai, Sudhen B ^a   Libutti, Steven K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Endothelial cells; Neovasculature; Tumor angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CD31 ANTIGEN; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 12; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; CANCER GROWTH; CANCER INHIBITION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CYTOKINES; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; GROWTH INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES;

EID: 0032911811     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199905000-00002     Document Type: Article

References (346)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. As reviewed in: Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43:175-203.
3. Fan T-PD, Jagger J, Bicknell R. Controlling the vasculature: angiogenesis, anti-angiogenesis, and vascular targeting of gene therapy. Trends Pharmacol Sci 1995;16:57-66.
4. As reviewed in: Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934.
5. As reviewed in: Diaz-Flores L, Gutierrez R, Varela H. Angiogenesis: An update. Histol Histopathol 1994;9:807-843.
6. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 1984;223:1296-1299.
7. Miyake H, Hara I, Yoshimura K, Eto H, Arakawa S, Wada S, Chihara K, Kamidono S. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. Cancer Res 1996;56:2440-2445.
8. Gualandris A, Rusnati M, Belleri M, Nelli EE, Bastaki M, Parolini S, Albini A, Morbidelli L, Ziche M, Corallini A, Possati L, Vacca A, Ribatti D, Presta M. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Grow Dijferen 1996;7:147-160.
9. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Nad Acad Sci USA 1986;83:7297-7301.
10. As reviewed in: Bikfalvi A. Significance of angiogenesis in tumor progression and metastasis. Eur J Cancer 1995;31:1101-1104.
11. Steger K, Tetens F, Seitz J, Grothe C, Bergmann M. Localization of fibroblast growth factor 2 (FGF-2) protein and the receptors FGFR 1-4 in normal human seminiferous epithelium. Histochem Cell Biol 1998;110:57-62.
12. Patry V, Bugler B, Maret A, Potier M, Prats H. Endogenous basic fibroblast growth factor isoforms involved in different intracellular protein complexes. Biochem J 1997;326:259-264.
13. Davis MG, Zhou M, Ali S, Coffin JD, Doetschman T, Dorn GW II. Intracrine and autocrine effects of basic fibroblast growth factor in vascular smooth muscle cells. J Mol Cell Cardiol 1997;29:1061-1072.
14. Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum Golgi complex. J Cell Physiol 1992;151:81-93.
15. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding antiogenic protein-basic fibroblast growth factor is stored within basement membrane. Am J Pathol 1988;130:393-400.
16. Andres JL, DeFalcis D, Noda M, Massague J. Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J Biol Chem 1992;267:5927-5930.
17. v integrins. Science 1995;270:1500-1502.
18. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, Shapiro RL, Galloway AC, Rifkin DB, Mignatti P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998;141:1659-1673.
19. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58:808-814.
20. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sei USA 1995;92:4562-4566.
21. Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 1988;48:2083-2088.
22. Tanimoto H, Yoshida K, Yokozaki H, Yasui W, Nakayama H, Ito H, Ohama K, Tahara E. Expression of basic fibroblast growth factor in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1991;61:263-267.
23. Folkman J, Szabo S, Stovroff M, McNeil P, Li W, Shing Y. Duodenal ulcer: discovery of a new mechanism and development of angiogenic therapy which accelerates healing. Ann Surg 1991;214:414-417.
24. Landau C, Jacobs AK, Haudenschild CC. Intrapericardial basic fibroblast growth factor induces myocardial angiogenesis in a rabbit model of chronic ischemia. Am Heart J 1995;129:924-931.
25. Loughman MS, Chatzistefanou K, Gonzalez EM, Flynn E, Adamis AP, Shing Y, D’Amato RJ, Folkman J. Experimental corneal neovascularization using sucralfate and basic fibroblast growth factor. Aust N Z J Ophthalmol 1996;24:289-295.
26. Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985.
27. Senger DR, Peruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor lines. Cancer Res 1986;46:5629-5632.
28. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990;50:1774-1778.
29. Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Lai IU, Oldfield EH. Expression of the vascular permeability factoryascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993;91:153-159.
30. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53: A121-A135.
31. Brown LF, Berse B, Jackman RW, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
32. Alon T, Hemo I, Itin A, Peer J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med 1995;1:1024-1028.
33. Keck PJ, Hauser SD, Krivi G, Snazo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312.
34. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987;57:673-686.
35. As reviewed in: Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
36. Houch KA, Ferrara N, Winer J, Cachianes G, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806-1814.
37. Ferrara N, Houck KA, Jakeman LB, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of protein. Endocrin Rev 1992;13:18-32.
38. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995;129:895-898.
39. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1990;87:2628-2632.
40. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992;187:1579-1586.
41. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth HP, Shawver LK. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56:3540-3545.
42. As reviewed in: Breier G, Damert A, Plate KH, Risau W. Angiogenesis in embryos and ischemic diseases. Thromb Haemost 1997;78:678-683.
43. Barleon B, Siemeister G, Martiny-Baron G, Weindel K, Herzog C, Marme D. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 1997;57:5421-5425.
44. Waltenberger J, Claesson-Welch L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995.
45. Jackson JR, Minton JAL, Ho ML, Wei N, Winkler JD. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin-lβ. J Rheumatol 1997;24:1253-1259.
46. Donovan D, Harmey JH, Toomey D, Osborne DH, Redmond HP, Bouchier-Hayes DJ. TGF beta-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol 1997;4:621-627.
47. Koochekpour S, Merzak A, Pilkington GJ. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. Cancer Lett 1996;102:209-215.
48. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, Kuwano M. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996;271:28220-28228.
49. As reviewed in: Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF. Vascular permeability factor/ vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997;79:233-269.
50. Detmar M, Yeo KT, Nagy JA, Van de Water L, Brown LF, Berse B, Elicker BM, Ledbetter S, Dvorak HF. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 1995;105:44-50.
51. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond) 1992;359:843-845.
52. Shima DT, Deutsch U, D’Amore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 1995;370:203-208.
53. Fontanini G, Boldrini L, Vignati S, Chine S, Basolo F, Silvestri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G. Bc12 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer 1998;34:718-723.
54. Seimeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996;56:2299-2301.
55. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997;90:3322-3331.
56. Petit AM, Rak I, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-1530.
57. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993;265:H586-H592.
58. 2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 1991;138:213-221.
59. Morbidelli L, Chang CH, Douglas JG, Granger HJ, Ledda F, Ziehe M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996;270:H411-H415.
60. Ziehe M, Morbidelli L, Choudhuri R, Zhang H-T, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625-2634.
61. Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7:53-64.
62. Kim KJ, Li B, Winer J, Armanini M, Gillett NA, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (Lond) 1993;362:841-844.
63. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrera N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-1797.
64. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effects on primary tumor growth. Cancer Res 1996;56:921-924.
65. Kondo S, Asano M, Suzuki H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 1993;194:1234-1241.
66. ]2]. Cancer Res 1995;55:5296-5301.
67. Asano M, Yukita A, Matsumoto T, Hanatani M, Suzuki H. An anti-VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998;17:185-190.
68. Kanai T, Konno H, Tanaka T, Baba M, Matsumoto K, Nakamura S, Yukita A, Asano M, Suzuki H, Baba S. Anti-tumor and antimetastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998;77:933-936.
69. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sei USA 1998;95:8795-8800.
70. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D’Amore PA, Miller JW. Inhibition of vascular endothelial growth factor factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Opthalmol 1996;114:66-71.
71. Miyazono K, Okabe T, Urabe A, Takahu C, Heldin H. Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 1987;262:4098-5002.
72. Zetter BR, Antoniades HN. Stimulation of human vascular endothelial growth by a platelet-derived growth factor and thrombin. J Supramol 1979;11:361-370.
73. As reviewed in: Griffiths L, Stratford IJ. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy. Br J Cancer 1997;76:689-693.
74. Finnis C, Dodsworth N, Pollit CE, Carr G, Sleep D. Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity. Eur J Biochem 1993;212:201-210.
75. As reviewed in: Heldin CH, Usuki K, Miyazono K. Platelet-derived endothelial cell growth factor. J Cell Biochem 1991;47:208-210.
76. Haraguchi M, Miyadera K, Uemura K, Furukawa T, Yamada K, Akiyama S. Angiogenic activity of enzymes. Nature (Lond) 1994;368:198.
77. O’Brien TS, Fox SB, Dickinson AJ, Turley H, Westwood M, Moghaddam A, Gatter KC, Bicknell R, Harris AL. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 1996;56:4799-4804.
78. Takahashi Y, Bucana CD, Akagi Y, Liu W, Cleary KR, Mai M, Ellis LM. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res 1998;4:429-434.
79. Tanigawa N, Amaya H, Matsumura M, Katoh Y, Kitaoka A, Aotake T, Shimomatsuya T, Rosenwasser OA, Iki M. Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma. Cancer Lett 1996;108:281-290.
80. Nagaoka H, Lino Y, Takei H, Morishita Y. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. Int J Oncol 1998;13:449-454.
81. Matsumura M, Chiba Y, Lu C, Amaya H, Shimomatsuya T, Horiuchi T, Muraoka R, Tanigawa N. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer. Cancer Lett 1998;128:55-63.
82. Saeki T, Tanada M, Takashima S, Saeki H, Takiyama W, Nishimoto N, Moriwaki S. Correlation between expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) and microvessel density in early-stage human colon carcinomas. Jpn J Clin Oncol 1997;27:227-230.
83. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, Hong K, Dewhirst MW. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996;56:5522-5528.
84. 2 gradients in solid tumors reveal a lack of correlation. Nature Med 1997;3:177-182.
85. Vaupel PM. Oxygenation of Small Tumors. In: Teicher BA, ed. Drug resistance in Oncology. New York: Marcel Dekker, New York, 1993:53-85.
86. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor-1 in transcriptional response to hypoxia. Proc Natl Acad Sei USA 1993;90:4304-4308.
87. As reviewed in: Dang CV, Lewis BC, Dolde C, Dang G, Shim H. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Bioenerg Biomembr 1997;29:345-354.
88. Costa-Giomi P, Caro J, Weinmann R. Enhancement by hypoxia of human erythropoietin gene transcription in vitro. J Biol Chem 1990;265:10185-10188.
89. Muraoka K, Shimizu K, Sun X, Zhang YK, Tani T, Hashimoto T, Yagi M, Miyazaki I, Yamamoto K. Hypoxia, but not reoxygenation, induces interleukin 6 gene expression through NF-kappa B activation. Transplantation 1997;63:466-470.
90. Bandyopadhyay RS, Phelan M, Faller DV. Hypoxia induces API-regulated genes and AP-1 transcription factor binding in human endothelial and other cell types. Biochim Biophys Acta 1995;1264:72-78.
91. Rupee RA, Baeuerle PA. The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-kappa B. Eur JBiochem 1995;234:632-640.
92. Levy AP, Levy NS, Goldberg MA. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem 1996;271:25492-25497.
93. Ishibashi H, Nakagawa K, Nakashima Y, Sueishi K. Conditioned media of carcinoma cells cultured in hypoxic microenvironment stimulate angiogenesis in vitro; relationship to basic fibroblast growth factor. Virchows Arch 1995;425:561-568.
94. Baird A, Durkin T. Inhibition of endothelial cell proliferation by type-beta transforming growth factor: interaction with acidic and basic fibroblast growth factors. Biochem Biophys Res Commun 1986;138:476-482.
95. Frater-Schroder M, Muller G, Birchmeier W, Bohlen P. Transforming growth factor beta inhibits endothelial cell proliferation. Biochem Biophys Res Commun 1986;137:295-302.
96. Massague J. The transforming growth factor-β family. A Rev Cell Bio 1990;567-641.
97. Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-β1 on in vitro angiogenesis. Expl Cell Res 1993;204:356-363.
98. Hsu S, Huang F, Friedman E. Platelet-derived growth factor-β increases colon cancer cell growth in vivo by a paracrine effect. J Cell Physiol 1995;165:239-245.
99. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K. Excessive production of transforming growth factor B1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochem Biophys Acta 1992;1137:189-196.
100. Choi Y-H, Choi K-C, Park Y-E. Relationship of transforming growth factor βl to angiogenesis in gastric carcinoma. JKMS 1997;12:427-432.
101. Ito N, Kawata S, Tamura S, Shirai Y, Kiso S, Tsushima H, Matsuzawa Y. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 1995;89:45-48.
102. Pertovaara L, Kaipanen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 1994;269:6271-6274.
103. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, et al. Transforming growth factor factor β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sei USA 1986;83:4167-4171.
104. Derynck R. The biological complexity of transforming growth factor-β. In: The Cytokine Handbook, Thompson A, ed. Academic Press, 1994.
105. Pepper MS, Belin D, Montesano R, Orci L, Vassalli I-D. Transforming growth factor-βl modulates basic fibroblast growth factor induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990;111:743-755.
106. Mignatti P, Mazzieri R, Rifkin DB. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol 1991;113:1193-1201.
107. Nicosia RF, Madri JA. The microvascular extracellular matrix. Developmental changes during angiogenesis in the aortic ringplasma clot model. Am J Pathol 1987;128:78-90.
108. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-1169.
109. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-1180.
110. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol 1998;8:529-532.
111. Witzenbichler B, Maisonpierre PC, Lones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 1998;273:18514-18521.
112. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998;83:233-240.
113. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature (Lond) 1990;348:555-557.
114. Tanaka Y, Kawamata H, Fujimoto K, Oyasu R. Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J Urol 1997;157:683-688.
115. Koyama H, Nishizawa Y, Hosoi M, Fukumoto S, Kogawa K, Shioi A, Morii H. The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possible involvement of cyclin-dependent kinase 2. Circ Res 1996;79:757-764.
116. Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, Biemann K, Liu JO. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 1997;4:461-471.
117. O’Reilly MS, Brem H, Folkman J. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg 1995;30:325-9. Discussion 329-30.
118. Yazaki T, Takamiya Y, Costello PC, Mineta T, Menon AG, Rabkin SD, Martuza RL. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J Neurooncol 1995;23:23-29.
119. Kalebic T, Tsokos M, Helman LJ. Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470. Int J Cancer 1996;68:596-599.
120. Isobe N, Uozumi T, Kurisu K, Kawamoto K. Experimental studies of the antitumor effect of TNP-470 on malignant brain tumors. Antitumor effect of TNP-470 on a human medulloblastoma xenograft line. Neuropediatrics 1996;27:136-142.
121. Miki T, Nonomura N, Nozawa M, Harada Y, Nishimura K, Kojima Y, Takahara S, Okuyama A. Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line. J Urol 1998;160:210-213.
122. Hama Y, Shimizu T, Hosaka S, Surgenoya A, Usuda N. Therapeutic efficacy of the angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice. Exp Toxicol Pathol 1997;49:239-247.
123. Singh Y, Shikata N, Kiyozuka Y, Nambu H, Morimoto J, Kurebayashi J, Hioki K, Tsubura A. Inhibition of tumor growth and metastasis by angiogenesis inhibitor TNP-470 on breast cancer cell lines in vitro and in vivo. Breast Cancer Res Treat 1997;45:15-27.
124. Sasaki A, Alcalde RE, Nishiyama A, Lira DD, Mese H, Akedo H, Matsumura T. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res 1998;58:462-467.
125. Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remick SC, Cooley TP, Moore J, Sommadossi JP, Shriver SL, Suckow CW, Gill PS. Fumagillin analog in the treatment of Kaposi’s sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998;16:1444-1449.
126. Angiolillo AL, Sgadari C, Tosato G. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann N ¥ Acad Sei 1996;795:158-167.
127. Angiolillo AL, Sgadari C, Taub DD, Liao F, Färber IM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-162.
128. Strieter RM, Kunkel SL, Arenburg DA, Burdick MD, Polverini PJ. Interferon-7-inducible protein 10 (IP-10), a member of C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun 1995;210:51-57.
129. Luster AD, Unkeless J, Ravetch J. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature (Lond) 1985;315:672-676.
130. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997;8:207-219.
131. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Färber JM, Pestka S, Trinchieri G, Lee WM. Tumor cell responses to IFN-gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:25-34.
132. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996;87:3877-3882.
133. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996;184:981-992.
134. O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
135. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndal S, McCance SG, O’Reilly MS, Llinas M, Folkman J. Kringle domains of human angiostatin. Characterization of the antiproliferative activity on endothelial cells. J Biol Chem 1996;271:29461-29467.
136. Kost C, Benner K, Stockmann A, Linder D, Preissner KT. Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur J Biochem 1996;236:682-688.
137. Barendsz-Janson AF, Griffioen AW, Muller AD, van Dam-Mieras MCE, Hillen HFP. In vitro tumor angiogenesis assays: Plasminogen lysine binding site 1 inhibits in vitro tumor-induced angiogenesis. J Vase Res 1998;35:109-114.
138. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Engchild J, Kwaan HC, Lee F, Kramer RA, Volpert OV, Bouck N, Soff GA. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proe Natl Acad Sei USA 1997;94:10868-10872.
139. Luo J, Lin J, Paranya G, Bischoff J. Angiostatin upregulates E-selectin in proliferating endothelial cells. Biochem Biophys Res Comm 1998;245:906-911.
140. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
141. Boehm T, Folkman J, Browder T, O’Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond) 1997;390:40-407.
142. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
143. Patan S. TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. Microvasc Res 1998;56:1-21.
144. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proe Natl Acad Sei USA 1994;91:4082-4085.
145. Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-978.
146. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998;236:461-466.
147. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998;55:1827-1834.
148. Gutman M, Szold A, Ravid A, Lazauskas T, Merimsky O, Klausner JM. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res 1996;16:3673-3677.
149. Lansing MB, Dixit S, Glaser B. Effect of systemic thalidomide and amiloride on neovascularization in the rabbit corneal micropocket assay. Invest Ophthalmol Vis Sei 1996;37:S658.
150. Tsujikawa M, Saito Y, Tatebayashi M, Tano Y. The inhibitory effect of thalidomide for experimental preretinal neovascularization by laser-induced venous occlusion in rats. Invest Ophthalmol Vis Sei 1996;37:S120.
151. Ip M, Gorin MB. Recurrence of a choroidal neovascular membrane in a patient with punctate inner choriopathy treated with daily doses of thalidomide. Am J Ophthalmol 1996;122:594-595.
152. Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996;7:339-343.
153. Pollard M. Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats. Cancer Lett 1996;101:21-24.
154. Hashimoto Y. Novel biological response modifiers derived from thalidomide. Curr Med Chem 1998;5:163-178.
155. Miyachi H, Azuma A, Hioki E, Iwasaki S, Kobayashi Y, Hashimoto Y. Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production. Biochem Biophys Res Commun 1996;224:426-430.
156. Tavares JL, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw RJ. Thalidomide reduces tumor necrosis factor-alpha production by human alveolar macrophages. Respir Med 1997;91:31-39.
157. Kohn EC, Sandeen MA, Liotta LA. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res 1992;52:3208-3212.
158. Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 1996;56:569-573.
159. Lambert PA, Somers KD, Kohn EC, Perry RR. Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines. Surgery 1997;122:372-378.
160. Jacobs W, Mikkelsen T, Smith R, Nelson K, Rosenblum ML, Kohn EC. Inhibitory effects of CAI in glioblastoma growth and invasion. J Neurooneol 1997;32:93-101.
161. Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A, Liotta LA, Reed E. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol 1997;15:1985-1993.
162. Lawler JW, Slayter HS, Coligan JE. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J Biol Chem 1978;260:3762-3772.
163. Silverstein RL, Baird M, Lo SK, Yesner LM. Sense and antisense cDNA transfection of CD36 (glycoprotein IV) in melanoma cells. Role of CD36 as a thrombospondin receptor. J Biol Chem 1992;267:16607-16612.
164. Hogg PJ, Stenflo J, Mosher DF. Thrombospondin is a slow tight-binding inhibitor of plasmin. Biochemistry 1992;31:265-269.
165. As reviewed in: Qian X, Tuszynski GP. Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med 1996;212:199-207.
166. As reviewed in: Mosher DF, Misenheimer TM, Stenflo J, Hogg PJ. Modulation of fibrinolysis by thrombospondin. Ann N Y Acad Sei 1992;667:64-69.
167. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
168. Salnikow K, Cosentino S, Klein C, Costa M. Loss of thrombospondin-1 transcriptional activity in nickel-transformed cells. Mol Cell Biol 1994;14:851-858.
169. Loganadane LD, Berge N, Legrand C, Fauvel-Lafeve F. Endothelial cell proliferation regulated by cytokines modulates thrombospondin-1 secretion into the subendothelium. Cytokine 1997;9:740-746.
170. Taraboletti G, Roberts D, Liotta LA, Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 1990;111:765-772.
171. Bagavandoss P, Wilks JW. Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem Res Commun 1990;170:867-872.
172. Bagavandoss P, Kaytes P, Vogell G, Wells PA, Wilks JW. Recombinant truncated thrombospondin-1 monomer modulates endothelial cell plasminogen activator inhibitor 1 accumulation and proliferation in vitro. Biochem Biophys Res Commun 1993;192:325-332.
173. Volpert OV, Dameron KM, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997;14:1495-1502.
174. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable for a fragment of thrombospondin. Proc Natl Acad Sei USA 1990;87:6624-6628.
175. Tolsma SA, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122:497-511.
176. Castle VP, Dixit VM, Polverini PJ. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells. Lab Invest 1997;77:51-61.
177. Hsu SC, Volpert OV, Steck PA, Mikkelsen T, Polverini PJ, Rao S, Chou P, Bouck NP. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 1996;56:5684-5691.
178. Castle VP, Ou X, O’Rourke K, Dixit VM. High levels of thrombospondin-1 expression in two NIH 3T3 cloned lines confers serum- and anchorage-independent growth. J Biol Chem 1993;268:2899-2903.
179. As reviewed in: Tuszynski GP, Nicosia RF. The role of thrombospondin-1 in tumor progression and angiogenesis. BioEssays 1996;18:71-76.
180. As reviewed in: Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997;15:675-705.
181. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Einer VM, Einer SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-1801.
182. Hu DE, Hory Y, Fan TP. Interleukin-8 stimulates angiogenesis in rats. Inflammation 1993;17:135-143.
183. Petzelbauer P, Watson CA, Pfau SE, Pober JS. IL-8 and angiogenesis: evidence that human endothelial cells lack receptors and do not respond to IL-8 in vitro. Cytokine 1995;7:267-272.
184. As reviewed in: Strieter RM, Polverini PJ, Arenberg DA, Walz A, Opdenakker G, Van Damme J, Kunkel SL. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol 1995;57:752-762.
185. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM. Inhibition of interleukin-8 reduces tumorigenesis of human nonsmall cell lung cancer in SCID mice. J Clin Invest 1996;97:2792-2802.
186. Kitadai Y, Haruma K, Sumii K, Yamamoto S, Ue T, Yokozaki H, Yasui W, Ohmoto Y, Kajiyama G, Fidler IJ, Tahara E. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Path 1998;152:93-100.
187. Yu WG, Yamamoto N, Takenaka H, Mu J, Tai XG, Zou JP, Ogawa M, Tsutsui T, Wijesuriya R, Yoshida R, Herrmann S, Fujiwara H, Hamaoka T. Molecular mechanisms underlying IFN-7-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol 1996;8:855-865.
188. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ III, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466-6474.
189. Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Färber JM, Liao F, Liu L, Tosato G. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 1998;64:384-392.
190. Voest EE, Kenyon BM, O’Reilly MS, Truitt G, D’Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-586.
191. Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 1998;78:361-365.
192. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomas with recombinant interferon alpha-2a. N Engl J Med 1989;320:1197-1200.
193. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-1463. (Errata, N Engl J Med 1994;330:300; 1995;333:595-596).
194. Folkman J. Clinical applications of research on angiogenesis. Semin Med Beth Israel Hosp 1995;333:1757-1763.
195. Fung WE. Interferon alpha-2a for treatment of age-related macular degeneration. Am J Ophthalmol 1991;112:349-350.
196. Park KC, Ahn PS, Lee YS, Kim KH, Cho KH. Treatment of angioblastoma with recombinant interferon-alpha 2. Pediatr Dermatol 1995;12:184-186.
197. Sexl V, Wagner L, Wiesholzer M, Presterl E, Base W. Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests. Clin Investig 1994;72:317-320.
198. Wojta J, Zoellner H, Gallicchio M, Filonzi EL, Hamilton JA, McGrath K. Interferon-alpha 2 counteracts interleukin-1 alpha-stimulated expression of urokinase-type plasminogen activator in human foreskin microvascular endothelial cells in vitro. Lymphokine Cytokine Res 1994;13:133-138.
199. Robinson SP, Goldstein D, Witt PL, Borden EC, Jordan VC. Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2. Breast Cancer Res Treat 1990;15:95-101.
200. Martyre MC, Beaupain R, Falcoff E. Potentiation of antiproliferative activity by mixtures of human recombinant IFN-alpha 2 and -gamma on growth of human cancer nodules maintained in continuous organotypic culture. Eur J Cancer Clin Oncol 1987;23:917-922.
201. As reviewed in: Stetler-Stevenson WG, Aznovoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastases. Annu Rev Cell Biol 1993;9:541-573.
202. Seiki M. Membrane type-matrix metalloproteinase and tumor invasion. Curr Top Microbio Immunol 1996;213:23-32.
203. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumor invasion, metastases, and angiogenesis. Eur Respir J 1994;7:2062-2072.
204. As reviewed in: Rabbani SA. Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 1998;12:135-142.
205. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, Basset P. Stromelysin 3 belongs to a subgroup of proteins expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sei USA 1993;90:1843-1847.
206. Porte H, Triboulet JP, Kotelevets L, Carrat F, Prevot S, Nordlinger B, DiGioia Y, Wurtz A, Comoglio P, Gespach C, Chastre E. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin Cancer Res 1998;4:1375-1782.
207. Thewes M, Worret WI, Engst R, Ring J. Stromelysin-3: a potent marker for histopathologic differentiation between desmoplastic trichoepithelioma and morphealike basal cell carcinoma. Am J Dermatopathol 1998;20:140-142.
208. Thewes M, Pohlmann G, Atkinson M, Mueller J, Putz B, Flofler H. Stromelysin-3 (ST-3) mRNA expression in colorectal carcinomas. Localization and clinicopathologic correlations. Diagn Mol Pathol 1996;5:284-290.
209. Karameris A, Panagou P, Tsilalis T, Bouros D. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. Am J Respir Crit Care Med 1997;156:1930-1936.
210. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (Land) 1990;348:699-704.
211. Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchell MA. Interstitial collagenase is required for angiogenesis in vitro. Develop Biol 1994;162:499-511.
212. Unemori EN, Ferrara N, Bauer EA, Amento EP. Vascular enthelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992;153:557-562.
213. Zucker S, Conner C, DiMassimo BI, Ende H, Drews M, Seiki M, Bahou WF. Thrombin induces the activation of progelatinase A in vascular endothelial cells: physiologic regulation of angiogenesis. J Biol Chem 1995;270:23730-23738.
214. Cawston TE, Galloway WA, Mercer E, Murphy G, Reynolds JJ. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981;195:159-165.
215. Welgus HG, Stricklin GP, Eisen AZ, Bauer EA, Cooney RV, Jeffrey JJ. A specific inhibitor of vertebrate collagenase produced by human skin fibroblasts. J Biol Chem 1979;254:1938-1943.
216. Stetler-Stevenson WG, Krutsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase family. J Biol Chem 1989;264:17374-17378.
217. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. TIMP-3 is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994;9352-9360.
218. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-f10 melanoma cells in vivo by the overexpression of tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994;86:299-304.
219. Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler-Stevenson WG, Oyasu R. Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer 1995;63:680-687.
220. Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989;108:671-682.
221. Johnson MD, Kim HR, Chesler L, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994;160:194-202.
222. Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, Abe R, Ueo H, Akiyoshi T. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 1997;76:531-536.
223. Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG, Albini A. TIMP-2 overexpression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998;75:246-253.
224. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991;83:775-779.
225. Li H, Lu H, Griscelli, Opolon P, Sun L-Q, Ragot T, Legrand Y, Belin D, Soria J, Soria C, Perricaudet M, Yeh P. Adenovirus mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Therapy 1998;5:1105-1113.
226. Gunzler WA, Steffens GJ, Otting F, Kim SM, Frankus E, Flohe L. The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe-Seyler’s Z Physiol Chem 1982;363:1155-1165.
227. Odekon LE, Blasi F, Rifkin DB. A requirement for receptorbound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J Cell Physiol 1994;158:396-407.
228. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, Goltzman D. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commum 1990;173:1058-1064.
229. Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 1997;420:79-85.
230. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997;100:58-67.
231. Ignar DM, Andrews JL, Witherspoon SM, Leray JD, Clay WC, Kilpatrick K, Onori J, Kost T, Emerson DL. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis 1998;16:9-20.
232. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996;56:2428-2433.
233. O’Mahony CA, Seidel A, Albo D, Chang H, Tuszynski GP, Berger DH. Angiostatin generation by human pancreatic cancer. J Surg Res 1998;77:55-58.
234. Yoo NC, Chung HC, Chung HC, Park JO, Rha SY, Kim JH, Roh JK, Min JS, Kim BS, Noh SH. Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. Yonsei Med J 1998;39:27-36.
235. Maurer CA, Friess H, Kretschmann B, Wildi S, Muller C, Graber H, Schilling M, Buchler MW. Over-expression of ICAM-1, VCAM-1, and ELAM-1 might influence tumor progression in colorectal cancer. Int J Cancer 1998;79:76-81.
236. Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996;56:1111-1117.
237. Stewart RJ, Kashxur TS, Marsden PA. Vascular endothelial platelet endothelial adhesion molecule-1 (PECAM-1) expression is decreased by TNF-alpha and IFN-gamma. Evidence for cytokine-induced destabilization of messenger ribonucleic acid transcripts in bovine endothelial cells. J Immunol 1996;156:1221-1228.
238. Kuppner MC, van Meir E, Flamou MF, de Tribolet N. Cytokine regulation of intercellular adhesion molecule-1 (ICAM-1) expression on human glioblastoma cells. Clin Exp Immunol 1990 Jul;81: 142-148.
239. Burno DK, Fabian DF, Lefor AT. ICAM-1 increases in vitro adhesion and cytotoxicity in a murine fibrosarcoma. J Surg Res 1996;60:398-402.
240. Sartor WM, Kyprianou N, Fabian DF, Lefor AT. Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumor growth rate. J Surg Res 1995;59:66-74.
241. Vazeux R, Hoffman PA, Tomita JK, Dickinson ES, Jasman RL, St John T, Gallatin WM. Cloning and characterization of a new intracellular adhesion molecule ICAM-R. Nature (Lond) 1992;360:485-488.
242. Fawcett J, Holness CLL, Needham LA, Turley H, Gatter KC, Mason DY, Simmons DL. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature (Lond) 1992;360:481-484.
243. Terol MJ, Cid MC, Lopez-Guillermo A, Juan M, Yague J, Miralles A, Vilella R, Vives J, Cardesa A, Montserrat E, Campo E. Expression of intercellular adhesion molecule-3 (ICAM-3/CD50) in malignant lymphoproliferative disorders and solid tumors. Tissue Antigens 1996;48:271-277.
244. Patey N, Vazeux R, Canioni D, Potter T, Gallatin WM, Brousse N. Intercellular adhesion molecule-3 on endothelial cells. Expression in tumors but not in inflammatory responses. Am J Pathol 1996; 148:465-472.
245. Kim CS, Wang T, Madri JA. Platelet endothelial cell adhesion molecule-1 expression modulates endothelial cell migration in vitro. Lab Invest 1998;78:583-590.
246. Albelda SM, Muller WA, Buck CA, Newman PJ. Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. J Cell Biol 1991;114:1059-1068.
247. Sheibani N, Frazier WA. Down-regulation of platelet endothelial cell adhesion molecule-1 results in thrombospondin-1 expression and concerted regulation of endothelial cell phenotype. Mol Biol Cell 1998;9:701-713.
248. Sheibani N, Newman PJ, Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, regulates platelet-endothelial cell adhesion molecule-1 expression and endothelial cell morphogenesis. Mol Biol Cell 1997;8:1329-1341.
249. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinsons CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 1997;151:671-677.
250. Mayer B, Spatz H, Funke I, Johnson JP, Schildberg FW. De novo expression of the cell adhesion molecule E-selectin on gastric cancer endothelium. Langenbecks Arch Surg 1998;383:81-86.
251. Giavazzi R, Foppolo M, Dossi R, Remuzzi A. Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions. J Clin Invest 1993;92:3038-3044.
252. Kraling BM, Razon MJ, Boon LM, Zurakowski D, Seachord C, Darveau RP, Mulliken JB, Corless CL, Bischoff J. E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol 1996:1181-1191.
253. Bischoff J, Brasel C, Kraling B, Vranovska K. E-selectin is upregulated in proliferating endothelial cells in vitro. Microcirculation 1997;4:279-287.
254. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature (Lond) 1995;376:517-519.
255. Budson AE, Ko L, Brasel C, Bischoff J. The angiogenesis inhibitor AGM-1470 selectively increases E-selectin. Biochem Biophys Res Commun 1996;225:141-145.
256. Nguyen M, Corless CL, Kraling BM, Tran C, Atha T, Bischoff J, Barsky SH. Vascular expression of E-selectin is increased in estrogen-receptor-negative breast cancer: a role for tumor-cellsecreted interleukin-1 alpha. Am J Pathol 1997;150:1307-1314.
257. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
258. Clarke EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995;233-239.
259. Dedhar S, Hannigan GE. Integrin cytoplasmic interactions and bidirectional transmembrane signaling. Curr Opin Cell Biol 1996;8:657-669.
260. Walz DA. Thrombospondin as a mediator of cancer cell adhesion in metastasis. Cancer and Metast Rev 1992;11:313-324.
261. Albelda SM. Role of integrins and other adhesion molecules in tumor prognosis and metastasis. Lab Invest 1993;68:4-17.
262. As reviewed in: Frisch SM, Ruoshlati E. Integrins and anoikis. Curr Opins Cell Biol 1997;9:701-706.
263. Van Waes C, Surh DM, Chen Z, Kirby M, Rhim JS, Brager R, Sessions RB, Poore J, Wolf GT, Carey TE. Increase in suprabasilar integrin adhesion molecule expression in human epidermal neoplasms accompanies increased proliferation occurring with immortalization and tumor progression. Cancer Res 1995;55:5434-5444.
264. As reviewed in: Van Waes C. Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Head Neck 1995;17:140-147.
265. As reviewed in: Preissner KT, May AE, Wohn KD, Germer M, Kanse SM. Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodeling. Thromb Haemost 1997;78:88-95.
266. Modlich U, Kaup FJ, Augustin HG. Cyclic angiogenesis and blood vessel regression in the ovary: blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion. Lab Invest 1996;74:771-780.
267. 5-directed cell motility but not adhesion on vitronectin. J Cell Biol 1994;127:859-866.
268. Enenstein J, Kramer RH. Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. J Invest Dermatol 1994;103:381-386.
269. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 expression on tumor-associated vessels of human carcinomas. Science 1994;264:569-571.
270. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ, De Waal RM. Immunohistochemical analysis of integrin alpha v beta 3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997;71:320-324.
271. Buckley CD, Doyonnas R, Newton JP, Blystone SD, Brown EJ, Watt SM, Simmons DL. Identification of alpha v beta 3 as a heterotypic ligand for CD31/PECAM-1. J Cell Sci 1996; 109 (Pt 2):437-445.
272. As reviewed in: Varner JA, Cheresh DA. Integrins and cancer. Curr Opins Cell Biol 1996;8:724-730.
273. 3 integrin promotes proliferation of colon carcinoma cells through a unique region of the (36 cytoplasmic domain. I Cell Biol 1994;127:547-556.
274. 3. Cell 1996;85:683-693.
275. As reviewed in: Varner JA, Brooks PC, Cheresh DA. The integrin alpha v beta 3: angiogenesis and apoptosis. Cell Adhes Commun 1995;3:367-374.
276. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-1822.
277. Carron CP, Meyer DM, Pegg JA, Engleman VW, Nickols MA, Settle SL, Westlin WF, Ruminski PG, Nickols GA. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res 1998;58:1930-1935.
278. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21 (WAF1/CIP1) expression by vascular cell integrin avb3 during angiogenesis. J Clin Invest 1996;98:426-433.
279. As reviewed in: Varner JA, Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin alpha v beta 3. Important Adv Oncol 1996;69-87.
280. Yano M, Iwama A, Nishio H, Suda J, Takada G, Suda T. Expression and function of murine receptor kinases, TIE and TEK, in hematopoietic stem cells. Blood 1997;12:4317-4326.
281. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature (Lond) 1995;376:70-74.
282. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 1995;14:5884-5891.
283. Partanen J, Puri MC, Schwartz L, Fischer KD, Bernstein A, Rossant J. Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during murine development. Development 1996;122:3013-3021.
284. McCarthy MJ, Crowther M, Bell PR, Brindle NP. The endothelial receptor tyrosine kinase tie-1 is upregulated by hypoxia and vascular endothelial growth factor. FEBS Lett 1998;423:334-338.
285. Dumont DJ, Gradwohl GJ, Fong G-H, Puri MC, Gersenstein M, Auerbach R, Breitman ML. Dominant negative and targeted null mutations in endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of embryo. Gene Dev 1994;8:1897-1909.
286. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997;81:567-574.
287. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sei USA 1998;95:8829-8834.
288. As reviewed in: Warzocha K, Bienvenu J, Coiffier B, Salles G. Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. Eur Cytokine Netw 1995;6:83-96.
289. As reviewed in: Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-1308.
290. Pronk GJ, Bos JL. The role of p21(ras) in receptor tyrosine signaling. Biochem Biophys Acta 1994;1198:131-147.
291. Rak J, Mitsuhshi Y, Erdos V, Huang SN, Filmus J, Kerbel R. Massive programmed cell death in intestinal epithelial cells induced by mutant c-H-ras oncogene expression. J Cell Biol 1995;131:1587-1598.
292. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddles JC, Abrahams JA. The human gene for vascular endothelial growth factors. J Biol Chem 1991;266:11947-11954.
293. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995:55:4575-4580.
294. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995;270:25915-25919.
295. Anzano M, Roberts A, Delarco J, Wakefield L, Assoian R, Roche N, Smith J, Lazarus J, Sporn M. Increased secretion of type beta transforming growth factor accompanies viral transformation of cells. Mol Cell Biol 1985;5:242-247.
296. Buick RN, Filmus J, Quaroni A. Activated H-ras transforms rat intestinal epithelial cells with expression of a-TGF. Exp Cell Res 1987;170:300-309.
297. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995;14:263-277.
298. James GL, Goldstein JL, Brown MS. Polylysine and DVIM sequences of K-rasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 1995;270:6221-6226.
299. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Grahan SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993;260:1934-1942.
300. As reviewed in: Gibbs JB, Olif A, Kohl NE. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 1994;77:175-178.
301. As reviewed in: Lowry DR, Willumsen BM. Rational cancer therapy. Nature Med 1995;1:747-748.
302. Kohl NE, Wilson FR, Mossier SD, Giuliani E, deSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee T-J, Smith RL, Graham SL, Hartman GD, Gibbs JB, Oliff A. Protein farnesyltransferase inhibitors block the growth of ras-independent tumors in nude mice. Proc Natl Acad Sei USA 1994;91:9141-9145.
303. Keiser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial cell growth factor expression. Oncogene 1994;9:363-369.
304. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995;55:6161-6165.
305. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ, Roth JA. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998;58:2288-2292.
306. Tory K, Brauch H, Linehan M, Barba D, Oldfield E, Filling-Katz M, Seizinger B, Nakamura Y, White R, Marshall FF, et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 1989;81:1097-1101.
307. As reviewed in: van den Berg A, Buys CH. Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chromosomes Cancer 1997;19:59-76.
308. Pa S. Claffey KP, Dvorak HF, Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 1997;272:27509-27512.
309. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Spl to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-5639.
310. Illiopoulos O, Levy AF, Jiang C, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sei USA 1996;93:10595-10599.
311. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996;56:2299-2301.
312. Stratmann R, Krieg M, Haas R, Plate KH. Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindautumor suppressor gene. J Neuropathol Exp Neurol 1997;56:1242-1252.
313. Clauss M, Murray JC, Vianna M, de Waal R, Thurston G, Nawroth P, Gerlach H, Gerlach M, Bach R, Familletti PC, Stern D. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J Biol Chem 1990;265:7078-7083.
314. Kao J, Houck K, Fan Y, Haehnel I, Libutti SK, Kayton ML, Grikscheit DW, Chabot J, Nowygrod R, Greenberg S, Kuang W-J, Leung DW, Hayward JR, Kisiel W, Heath M, Brett J, Stern DM. Characterization of a novel tumor-derived cytokine: endothelial-monocyte activating polypeptide II. J Biol Chem 1994;269:25106-25119.
315. Kao J, Ryan J, Brett G, Chen J, Shen H, Fan Y-G, Godman G, Familletti PC, Wang F, Pan Y-CE, Stern D, Clauss M. Endothelial monocyte-activating polypeptide II: a novel tumor-derived polypeptide that activates host-response mechanism. J Biol Chem 1992;267:20239-20247.
316. Marvin MR, Libutti SK, Kayton M, Kao J, Hayward J, Grikscheit T, Fan Y, Brett J, Weinberg A, Nowygrod R, LoGerfo P, Feind C, Hansen KS, Schwarz M, Stern D, Chabot J. An novel tumorderived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. J Surg Res 1996;63:248-255.
317. Wu PC, Alexander HR, Huang J, Hwu P, Gnant M, Berger AC, Turner E, Wilson O, Libutti SK. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-a is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res 1999;59:205-212.
318. As reviewed in: Klagsbrun M, D’Amore PA. Regulators of angiogenesis. Ann Rev Physiol 1991;53:217-239.
319. Sunderkotter C, Growebler M, Schulze-Ostoff K, Bhardwaj R, Sorg C. Macrophage-derived angiogenesis factors. Pharmac Ther 1991;51:195-216.
320. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sei USA 1987;84:5277-5281.
321. Leibovich S, Polverini P, Shepard H, Wiseman D, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-ce. Nature (Lond) 1987;329:630-632.
322. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997;17:4015-4023.
323. Stolpen A, Guinan E, Fiers W, Pober J. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Path 1986;123:16-24.
324. Sato N, Goto T, Haranaka K, Satomi N, Nariuchi H, Mano-Hirano Y, Sawasaki T. Actions of tumor necrosis factor on cultured vascular endotheial cells. J Natl Cancer Inst 1986;76:1113-1121.
325. Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee M-E, Haber E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-a in cultured human vascular endothelial cells. J Clin Invest 1996;98:490-496.
326. BenEzra D, Hemo I, Maftzir G. In vivo angiogenic activity of interleukins. Arch Opthalmol 1990;108:573-576.
327. Renard N, Nooijen PT, Schalkwijk L, De Waal RM, Eggermont AM, Lienard D, Kroon BB, Lejeune FJ, Ruiter DJ. von Will-ebrand Factor release and platelet aggregation in human melanoma after perfusion with TNF-a. J Pathol 1995;176:279-287.
328. Declercq W, Denecker G, Fiers W, Vandenabeele P. Cooperation of both TNF receptors in inducing apoptosis: involvement of the TNF receptor-associated factor binding domain of the TNF receptor 75. J Immunol 1998;161:390-399.
329. Griffioen AW, Damen CA, Blijham GH, Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996;88:667-673.
330. Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC. Dual role of tumor necrosis factor alpha in angiogenesis. Am J Pathol 1992;140:539-544.
331. Okamura K, Sato Y, Matusuda T, Hamanaka R, Ono M, Kohno K, Kuwano M. Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in tumor necrosis factor-treated human microvascular endothelial cells. J Biol Chem 1991;266:19162-19165.
332. Mawatari M, Kohno K, Mizoguchi H, Matsuda T, Asoh K, van Damme J, Welgus HG, Kuwano M. Effects of tumor necrosis factor and epidermal growth factor on cell morphology, cell surface receptors, and the production of tissue inhibitor of metallo-proteinases and IL-6 in human microvascular endothelial cells. J Immunol 1989;143:1619-1627.
333. Mawatari M, Okamura K, Matsuda R, Hamanaka R, Mizoguchi H, Higashio K, Kohno K, Kuwano M. Tumor necrosis factor and epidermal growth factor modulate migration of human microvascular endothelial cells and production of tissue-type plasminogen activator and its inhibitor. Exp Cell Res 1991;192:574-578.
334. Sato Y, Okamura K, Morimoto A, Hamanaka R, Hamaguchi K, Shimada T, Ono M, Kohno K, Sakata T, Kuwano M. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res 1993;204:223-229.
335. Defilippi P, Truffa G, Stefanuto G, Altruda F, Silengo L, Tarone G. Tumor necrosis factor alpha and interferon gamma modulate the expression of the vitronectin receptor (integrin beta 3) in human endothelial cells. J Biol Chem 1991;266:7638-7645.
336. As reviewed in: Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1-8.
337. As reviewed in: Bach R. Tissue factor. Crit Rev Biochem 1988;23:339-368.
338. Mulder AB, Blom NR, Smit JW, Ruiters MI, Van Der Meer J, Haile MR, Bom VJ. Basal tissue factor expression in endothelial cell cultures is caused by contamination of smooth muscle cells. Reduction by using Chymotrypsin instead of collagenase. Thrombosis Res 1995;80:399-411.
339. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134:1087-1097.
340. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor Vila and tissue factor. Lancet 1995 Oct 14;346:1004-1005.
341. Costantini V, De Monte P, Cazzato AO, Stabile AM, Deveglia R, Frezzato E, Paolucci MC. Systemic thrombin generation in cancer patients is correlated with extrinsic pathway activation. Blood Coagul Fibrinolysis 1998;9:79-84.
342. Silberberg JM, Gordon S, Zucker S. Identification of tissue factor in two human pancreatic cancer cell lines. Cancer Res 1989;49:5443-5447.
343. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-550.
344. Clauss M, Weich H, Breier G, Kneis URW, Waltenberger J, Risau W. The vascular endothelial cell growth factor receptor flt-1 mediates biological activity. Implications for a functional role of placental growth factor in monocyte activation and chemotaxis. J Biol Chem 1996;271:17629-17634.
345. Bikfalvi A, Sauzeau C, Moukadiri J, Maclouf J, Busso N, Bryckaert M, Plout J, Tobelem G. Interaction of vasculotropin/vascular endothelial growth cell factor with human umbilical vein endothelial cells; binding, internalization, degradation, and biological effects. J Cell Physiol 1991;149:50-59.
346. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-1327.